GlaxoSmithKline Manufacturing S.p.A. (manufacturer of unpackaged products and quality control)
UkraineAll drugs from this manufacturer
-
The drug is prescribed to adults for the treatment of unresectable or metastatic melanoma with a BRAF V600 gene mutation. It is also used for the adjuvant treatment of stage III melanoma after complete resection and for the treatment of advanced non-small cell lung cancer with a BRAF V600 mutation.
Dosage form: tablets, film-coated
Active substance Dosage trametinib 0.5 mg ATC: L01EE01
-
The drug is prescribed to adults for the treatment of unresectable or metastatic melanoma with a BRAF V600 gene mutation, as well as for the adjuvant treatment of stage III melanoma after complete resection. Additionally, it is used for the treatment of advanced non-small cell lung cancer with a BRAF V600 mutation.
Dosage form: tablets, film-coated
Active substance Dosage trametinib 2 mg ATC: L01EE01